Minireviews
Copyright ©The Author(s) 2016.
World J Hepatol. Aug 28, 2016; 8(24): 1012-1018
Published online Aug 28, 2016. doi: 10.4254/wjh.v8.i24.1012
Table 1 Available literature on the potential correlation between non-selective beta blockers and mortality in patients with cirrhosis
Ref.PatientsRefractory ascitesPropranolol dose/dayFollow-upMortalitySepsis
Serstè et al[22]74100%40 mg (9); 80 mg (31); 120 mg (1); 160 mg (36)8 mo63/77 (P < 0.0001 vs No NSBB)NA
Galbois et al[40]2614 (53.8%)NA6 mo21/26 (80.8%)100%
Robins et al[60]36100%48.910 mo18/36 (50%) survival 18 moNA
Mandorfer et al[39]245100%40 mg (20-120)660 persons/yearHigher transplant free survival (HR = 0.771, P = 0.044)No correlation between NSBB and SBP (HR = 0.728, P = 0.211)
Kimer et al[31]23100%80 mg (40-200)Retrospective15/23 (65.2%)NA
Leithead et al[30]159 (119 on propranolol)NA80 mg (10-240)Retrospective35/159 (22%)NA
Bossen et al[32]55946%NA12 mo125/559 (22.5%)NA
Mookerjee et al[37]164 (propranolol 111; nadolol 6; carvedilol 16; other 31)NA40 (20-80; propranolol)NA40/164 vs 63/184 (24.4% vs 34.1%, P = 0.048)NA
Similar 6 and 12-mo mortality between groups (P = 0.64 and 0.35 respectively)
Pereira et al[33]104NANANA67% vs 69% (P = ns)21% vs 42% (P = ns)
Mallawaarachchi et al[34]75 (8 propranolol)NANA28 mo60% vs 66% (P = ns)NA
Bhutta et al[35]308 (nadolol 155; propranolol 64; carvedilol 72, other 62)NANANAMean survival: 58 d in NSBB group (vs 32 d of control group; P = 0.033)NA
Onali et al[36]126100%NA4 mo20 vs 60 (16% vs 32%; P = 0.002)NA